IMC Chicago’s Ginkgo Bioworks DNA Stock Holding History

IMC Chicago’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$334K	Buy	33,700 +7,700	+30%	+$64.4K	﹤0.01%	5108
2026 Q1	$159K	Sell	26,000 -22,000	-46%	-$183K	﹤0.01%	5141
2025 Q4	$399K	Buy	48,000 +7,400	+18%	+$79.7K	﹤0.01%	3618
2025 Q3	$592K	Buy	+40,600	New	+$486K	﹤0.01%	3061

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

IMC Chicago's DNA Position: Q2 2026 in Review

IMC Chicago increased its Ginkgo Bioworks (DNA) stake by 19% in Q2 2026, buying an estimated $31.9K and bringing the position to 24,311 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #5463.

IMC Chicago first reported a position in DNA in Q1 2026 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

IMC Chicago held 24,311 shares of Ginkgo Bioworks worth $241K as of Q2 2026.
IMC Chicago bought 3,810 Ginkgo Bioworks shares in Q2 2026, an estimated $31.9K.
Ginkgo Bioworks made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #5463 holding.
IMC Chicago first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 2 quarters since.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.